Compare Charles River Laboratories Intl. Inc (CRL) vs Cenovus Energy Inc (CVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Cenovus Energy Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $302.69 (market cap $14.23B), while Cenovus Energy Inc trades at $31.51 (market cap $57.90B). The key difference: Cenovus Energy Inc is far larger — about 4.1× Charles River Laboratories Intl. Inc's market cap, and Cenovus Energy Inc pays a 1.97% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Cenovus Energy Inc for 46 Days on average.
| CRL | CVE | |
|---|---|---|
Market Cap | $14.23B | $57.90B |
Volume | 1,176,885 | 7,863,588 |
Sector | Health | Energy |
52-Week High | $310.77 | $33.92 |
52-Week Low | $149.93 | $15.85 |
Typical Hold Time | 33 Days | 46 Days |
Enterprise Value | $17.06B | $63.84B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
Cenovus Energy (CVE) trades at $31.53, up 2.94% with a bullish technical signal and strong institutional support. The stock shows solid fundamentals with a P/E of 12.43, net income margin of 11.48%, and consistent earnings beats in recent quarters. Recent analyst upgrades and positive media coverage highlight the company's attractive valuation and growth prospects in the energy sector.
Outlook remains positive with projected 2026 revenue of $58.0B and net income of $6.7B, though investors should monitor oil price volatility and execution risks. Analyst consensus leans bullish with 11 buy ratings versus 1 sell, while technical indicators suggest potential resistance near $32.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →
